A Vaccine for Melioidosis?
https://www.youtube.com/embed/1etl51ditUw
This event too place online on 18 Maye 2022 via Zoom
About the Seminar: A talk followed by an open forum/Q&A
This seminar was the second in our "A Vaccine for" seminar series, in which leading experts will provided an overview of the state of vaccine research for VAIDATE’s focus pathogens. In "A Vaccine for Melioidosis?", Prof Mukhopadhyay and Dr Dastidar discussed the prospects for a vaccine for Melioidosis, the disease caused by a bacterium, Burkholderia pseudomallei, which is found across tropical and semi-tropical regions worldwide. It is estimated that 165,000 people develop melioidosis annually with 89,000 of these cases being fatal.
Speakers:
Chiranjay Mukhopadhyay is a Professor of Clinical Microbiology at the Kasturba Medical College, India and an authority on melioidosis on the Indian subcontinent. He has worked for more than a decade from South-western coastal part of India and has diagnosed more than 300 patients with melioidosis all over the India. He is one of the founder executive committee members of International Melioidosis Society (IMS) and the coordinator of Centre for Emerging and Tropical Diseases.
Other than Melioidosis, he is interested in research on Antimicrobial Resistance and Hospital Acquired Infections.
Dr. Somasish Ghosh Dastidar is a Ramalingaswami Fellow at Kasturba Medical College, India. Somasish's postdoctoral training was focused on neurodegeneration and aging, where he learned the relevance of noncoding RNA, autophagy, proteasomal degradation and chaperone machinery during aging disorders such as Parkinson’s and ALS. More recently, Somasish joined MAHE, his focus continues in ageing and age-related neurodegenerative disorders and tropical infectious diseases such as Melioidosis. He is an active collaborator with Prof. Chiranjay Mukhopadhyay to decipher the molecular mechanisms behind the aetiology of Burkholderia strains in the Indian Subcontinent.
Somasish is a firm believer in collaborative scientific ventures and has collaborators in India, USA and Brazil.
